Suppliers / Dishman Carbogen Amcis

Dishman Carbogen Amcis

India DCAL.BO Updated 9 July 2026

Dishman Carbogen Amcis is an API manufacturer based in India. It holds 11 active US drug master files across a filed portfolio of 15 molecules. Its GMP standing is certified by US FDA and EMA. Its most recent recorded inspection, by US FDA, closed on 12 June 2025 as NAI. Customs aggregates show $28.9M of exports covering 396 molecules to 49 destinations in 2025.

11
active US DMFs
0
valid CEPs
2
registered plants 2 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
2 of 2 confirmed
Inspections
8 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 12 June 2025 NAI US FDA
  • 7 March 2024 VAI US FDA
  • 15 February 2019 NAI US FDA
  • 26 October 2018 VAI US FDA
  • 8 July 2016 VAI US FDA
  • 22 October 2015 VAI US FDA
  • 2 May 2013 NAI US FDA
  • 17 March 2012 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Ahmedabad, India 3004161218
Ahmedabad, India 1000607691

What they file, and where

Molecule Regulators Docs
Bupivacaine US FDA 2
Cetylpyridinium SFDA (Saudi Arabia), US FDA 2
Pralidoxime SFDA (Saudi Arabia), US FDA 2
Ropivacaine SFDA (Saudi Arabia), US FDA 2
Bisacodyl US FDA 1
Bosentan SFDA (Saudi Arabia) 1
Cetrimide US FDA 1
Cetylpiridinium SFDA (Saudi Arabia) 1
Dimethyl SFDA (Saudi Arabia) 1
Eprosartan US FDA 1
Show all 15 molecules on file
Indigotindisulfonic Acid US FDA 1
Isosulfan Blue US FDA 1
Sodium Picosulfate US FDA 1
Sodium Picosulphate SFDA (Saudi Arabia) 1
Valganciclovir SFDA (Saudi Arabia) 1

Also appears on these molecule pages

Bisacodyl contract manufacturing Bosentan API Bupivacaine API Dimethyl API Eprosartan API Isosulfan Blue API Ropivacaine API Valganciclovir API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 2
EMA None 1

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $2.6M 31
2025 $311.2M $28.9M 49
2024 $312.6M $31.6M 50
2023 $292.2M $31.3M 54

Export figures are customs aggregates. We do not publish the identity of any buyer. Revenue shown in US dollars, converted from the reported currency.

Questions about Dishman Carbogen Amcis

Does Dishman Carbogen Amcis hold a US DMF or a CEP?
Dishman Carbogen Amcis holds 11 active US drug master files. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Dishman Carbogen Amcis FDA-registered?
2 sites operated by Dishman Carbogen Amcis carry an FDA establishment identifier (FEI), which means they are registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Dishman Carbogen Amcis's last inspection go?
The most recent inspection on record closed on 12 June 2025 as NAI (No Action Indicated: nothing objectionable was found). 8 inspections are on file.
Where does Dishman Carbogen Amcis manufacture?
2 registered sites are on record, in India (Ahmedabad among others). Every site is listed on this page with the register it came from.
What does Dishman Carbogen Amcis make?
15 molecules are on record against Dishman Carbogen Amcis, including Bupivacaine, Cetylpyridinium, Pralidoxime and Ropivacaine. Each links through to that molecule's full manufacturer list.
Which regulators recognise Dishman Carbogen Amcis's GMP?
Current GMP certificates are on record from US FDA and EMA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Dishman Carbogen Amcis comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 1 active litigation matter is on record.
  • The most recent inspection outcome was NAI, on 12 June 2025.

Comparable suppliers

Apitoria Pharma shares 4 molecules Jubilant Biosys shares 3 molecules Apex Healthcare shares 3 molecules MSN Laboratories shares 2 molecules Hetero shares 2 molecules

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts
Company filings
Revenue as reported